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Summary
Background The antibacterial, anti-inflammatory, and antiviral properties of azithromycin suggest therapeutic 
potential against COVID-19. Randomised data in mild-to-moderate disease are not available. We assessed whether 
azithromycin is effective in reducing hospital admission in patients with mild-to-moderate COVID-19.
Methods This prospective, open-label, randomised superiority trial was done at 19 hospitals in the UK. We enrolled 
adults aged at least 18 years presenting to hospitals with clinically diagnosed, highly probable or confirmed COVID-19 
infection, with fewer than 14 days of symptoms, who were considered suitable for initial ambulatory management. 
Patients were randomly assigned (1:1) to azithromycin (500 mg once daily orally for 14 days) plus standard care or to 
standard care alone. The primary outcome was death or hospital admission from any cause over the 28 days from 
randomisation. The primary and safety outcomes were assessed according to the intention-to-treat principle. This 
trial is registered at ClinicalTrials.gov (NCT04381962) and recruitment is closed.
Findings 298 participants were enrolled from June 3, 2020, to Jan 29, 2021. Three participants withdrew consent and 
requested removal of all data, and three further participants withdrew consent after randomisation, thus, the primary 
outcome was assessed in 292 participants (145 in the azithromycin group and 147 in the standard care group). The 
mean age of the participants was 45·9 years (SD 14·9). 15 (10%) participants in the azithromycin group and 17 (12%) in 
the standard care group were admitted to hospital or died during the study (adjusted OR 0·91 [95% CI 0·43–1·92], 
p=0·80). No serious adverse events were reported.
Interpretation In patients with mild-to-moderate COVID-19 managed without hospital admission, adding 
azithromycin to standard care treatment did not reduce the risk of subsequent hospital admission or death. Our 
findings do not support the use of azithromycin in patients with mild-to-moderate COVID-19.
Funding National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford and Pfizer.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Azithromycin is an orally active synthetic macrolide 
antibiotic with a wide range of antibacterial, anti-inflam-
matory, and antiviral properties.1 Early in 2020 it was 
highlighted by in silico and in vitro2 screens as a potential 
candidate therapy to be repurposed for treatment of 
COVID-19. Macrolides, particularly azithromycin, have 
previously been used to treat other viral infections, 
including one in three severe cases of MERS-CoV,3 
although randomised controlled trial data for its use in 
any coronavirus disease were absent.4 Azithromycin is 
inexpensive, safe, and widely available, and—stimulated 
by a small, non-randomised clinical report5—its use in 
the context of COVID-19 has become widespread in 
clinical practice and clinical trials.
In vitro azithromycin has broad antiviral activity against 
human viruses, including human rhinovirus, Zika virus, 
enteroviruses, Ebola virus, SARS-CoV,1 and against SARS-
CoV-2, being shown to reduce viral replication alone2 or in 
combination with hydroxy chloroquine.6 Azithromycin was 
also associated with reduced viral load of non-SARS-CoV-2 
alphacoronaviruses and betacoronaviruses in children 
receiving azithromycin during a mass distribution 
programme.7 Although antivirals probably have little 
efficacy in severe disease after viraemia has peaked,8–10 
azithromycin does have anti-inflammatory properties, 
including dose-dependent suppression of lymphocyte 
expression of perforin, and a range of proinflammatory 
cytokines, including IL-1β, IL-6, and TNF, IL-8 (CXCL8), 
IL-18, G-CSF, and GM-CSF11,12 and other components of 
the IL-1β–IL-6-induced acute phase response such as 
serum amyloid protein A.12
Despite these theoretical considerations, large-scale 
clinical trials of azithromycin either alone or co-
administered with hydroxychloroquine have not shown 
clinical efficacy in reducing mortality, need for invasive 
mechanical ventilation, duration of hospital admission, 
or clinical status on ordinal outcome scores in patients 
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admitted to hospital with COVID-19.13–16 However, these 
trials were all done in late-stage, severe disease with 
17–40% mortality. They did not study patients at earlier 
stages of disease in the community and are not able to 
make conclusions about the effectiveness of azithromycin 
outside the hospital setting. The efficacy of therapies in 
COVID-19 depends on the timing in the course of disease 
and in the populations being studied. Dexamethasone 
showed a strong survival benefit with treatment in 
patients with severe COVID-19 but no benefit, or even 
potential harm, in those not requiring oxygen therapy.17 
Conversely, studies of neutralising antibodies showed 
benefits in early disease18 but not in patients admitted 
to hospital.19 The antiviral and anti-inflammatory 
properties of azithromycin are suited to earlier-stage 
disease; thus, we studied an ambulatory population to 
establish whether it averts disease progression.
We did a randomised, open-label clinical trial to 
establish whether azithromycin is effective in preventing 
hospital admission or death in adult patients with 
clinically diagnosed COVID-19 infection being managed 
on an ambulatory care pathway.
Methods
Study design
ATOMIC2 was a prospective, open-label, two-arm, 
randomised superiority trial of standard care and azithro-
mycin compared with standard care alone, done at 
19 hospitals in the UK. The trial was done according to 
the published protocol, version 7.0 (appendix p 87)20 and 
all applicable laws and regulations including, but not 
limited to, the principles as stated in the International 
Council for Harmonisation Guideline for Good Clinical 
Practice, the standards set out by the Research Governance 
Framework, the Medicines for Human Use (Clinical 
Trials) Regulations 2004, and the ethical principles that 
have their origin in the Declaration of Helsinki. Safety 
data were reviewed and monitored by an independent 
data safety monitoring committee. The trial protocol was 
reviewed and approved by the UK Medicines and 
Healthcare products Regulatory Agency and an 
independent ethical committee (London—Brent Research 
Ethics Committee, reference number 20/HRA/2105).
Participants
Eligible participants were adults aged at least 18 years 
assessed in an acute hospital with a clinical diagnosis of 
highly probable or confirmed COVID-19 infection made 
by the attending clinical team, with onset of first 
symptoms within the past 14 days, and assessed by 
the attending clinical team as appropriate for initial 
ambulatory (ie, outpatient) management. Attendance for 
assessment in secondary care will have occurred via 
referral from primary care, or a national helpline, or 
self-referral. Key exclusion criteria were known 
hypersensitivity to any macrolide or the excipients, 
fructose intolerance, glucose-galactose malabsorption 
or sucrose-isomaltase insufficiency, current therapy 
with a macrolide antibiotic, hydroxychloroquine, or 
chloroquine, significant myocarditis, prolongation of a 
corrected QT interval (QTc) of more than 480 msec, 
significant electrolyte disturbance, clinically relevant 
Research in context
Evidence before this study
We searched MEDLINE and the Cochrane Central register of 
Controlled Trials with the terms (“azithromycin”) AND (“COVID” 
OR “COVID-19”) AND (“clinical trials”), until March 25, 2021, 
with no language restrictions. We identified 42 studies, among 
which there were four completed randomised trials of 
azithromycin (with or without hydroxychloroquine) in patients 
admitted to hospital with severe COVID-19 disease, and 
three completed randomised trials of azithromycin in patients 
with mild COVID-19 in primary care. The four randomised trials 
in patients admitted to hospital assigned 8988 participants to 
azithromycin or standard care or hydroxychloroquine and found 
no evidence of a difference in mortality, duration of hospital 
stay, or peak disease severity. The three trials in primary care 
settings randomly assigned participants with early disease to 
3 days or 5 days of therapy, and only one assessed azithromycin 
as standalone therapy. That trial was a large, adaptive platform 
trial in the UK that randomly assigned 540 participants in 
primary care to 3 days of treatment with azithromycin and 
875 participants to standard care alone and found no 
meaningful difference in time to first reported recovery or in 
rates of hospital admission (3% in both groups), and there were 
no deaths. We did not identify any randomised trials in patients 
with COVID-19 managed in ambulatory care.
Added value of this study
The ATOMIC2 trial was uniquely designed to assess 
azithromycin as a standalone therapy in those with mild-to-
moderate COVID-19 presenting to emergency care but assessed 
as appropriate for initial ambulatory management without 
hospital admission. ATOMIC2 also uniquely assessed high-dose, 
long-duration treatment to investigate the efficacy of putative 
anti-inflammatory effects. We found that azithromycin 500 mg 
daily for 14 days did not reduce the proportion of participants 
who died or required hospital admission from any cause over 
the 28 days from randomisation compared with standard care.
Implications of all the available evidence
Our findings, taken together with existing data, suggest there is 
no evidence that azithromycin reduces hospital admission, 
respiratory failure, or death compared with standard care, 
either in early disease in the community, or those admitted to 
hospital with severe disease, or in those with moderate disease 
managed on an ambulatory pathway.
See Online for appendix
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bradycardia, ventricular tachycardia, unstable severe 
cardiac insufficiency, and inability to understand written 
English. The full protocol including a complete list of 
inclusion and exclusion criteria are in the 
appendix (pp 112–13).20 All patients provided electronic 
informed consent before randomisation.
Randomisation and masking
Patients were randomly assigned (1:1) to either azithro-
mycin plus standard care or standard care alone using 
a web-based automated service, with a minimisation 
algorithm to ensure balanced allocation across treatment 
groups, stratified by centre, sex, and presence of hyper-
tension and diabetes. To ensure the unpredictability 
of treatment allocation, the first 30 participants were 
randomly assigned by simple randomisation and the 
minimisation algorithm included a probabilistic element 
(participants had an 80% chance of being allocated to the 
treatment, which minimised imbalance between the 
groups). Patients, investigators, and health-care providers 
were not masked to study drug assignment.
Procedures
Data on demographics, medical history, symptoms, risk 
factors for disease progression, and disease severity (age, 
male sex, hypertension, cardiovascular disease, diabetes, 
chronic lung disease, and cancer) were collected on all 
patients at baseline. Results were recorded for vital signs 
(temperature, respiratory rate, heart rate, blood pressure, 
and oxygen saturation), physical examination (including 
chest auscultation) with clinical assessment including the 
COVID Core Outcomes Set21 (a widely-used consensus set 
of clinical outcomes arising from a Delphi survey), and a 
nine-level severity score of respiratory illness (0–8, where 
0 indicates “Ambulatory. No limitation of activities” and 
8 indicates “Death”). Participants also had a 12-lead 
electrocardiogram. Optional study samples were taken at 
baseline and on one further occasion if the participant was 
admitted: oropharyngeal swab for SARS-CoV-2 PCR and 
nasal and blood samples for RNA transcriptomic analysis. 
Bloods and chest x-rays were done if clinically required.
Patients in the azithromycin group received 500 mg 
azithromycin once daily orally plus standard care for 
14 days and those in the control group received standard 
care according to local guidelines. Use of corticosteroids, 
other immunomodulators, antibiotics, and antivirals was 
permitted after randomisation, but the protocol excluded 
concomitant use of quinolone or macrolides antibiotics at 
enrolment or during follow-up. Subsequent assessments 
were conducted by telephone at days 14 and 28, and 
radiology results and clinical notes were assessed daily 
during hospital admission if this occurred.
Outcomes
The primary outcome was the proportion of participants 
with hospital admission or death from any cause within 
28 days from randomisation.
Secondary outcomes were the proportion of parti-
cipants with hospital admission with respiratory failure 
requiring non-invasive mechanical ventilation or 
invasive mechanical ventilation or death from any cause 
within 28 days from randomisation; the proportion of 
participants with hospital admission with respiratory 
failure requiring invasive or non-invasive mechanical 
ventilation support or death from any cause over 28 days 
from randomisation among those with a PCR-confirmed 
diagnosis of COVID-19 at randomisation; mortality or 
all-cause hospital admission amongst those with a 
PCR-confirmed diagnosis; all-cause mortality at day 28; 
the proportion progressing to clinician-diagnosed pneu-
monia; the proportion progressing to severe pneumonia; 
and differences in the peak severity of respiratory illness 
according to a nine-level ordinal severity score for 
clinical condition (appendix p 116). We also assessed 
safety and tolerability of azithromycin based on serious 
adverse events.
Statistical analysis and protocol changes
We had originally planned for the trial to recruit up to 
800 participants and use the following primary outcome: 
the proportion of participants with hospital admission 
with respiratory failure requiring non-invasive mecha-
nical ventilation or invasive mechanical ventilation or 
death from any cause within 28 days from randomisation. 
However, a decision was made at the preplanned interim 
analysis of 109 participants reaching the 28-day post-
randomisation timepoint to update the primary outcome, 
Figure 1: Trial profile
*These participants withdrew completely and asked for all their data collected to 
date to be removed; therefore, they have not been included in any summaries or 
analyses.
147 randomly assigned to
azithromycin
2 withdrew
3 withdrew and requested that 





1192 patients assessed for eligibility
298 enrolled
145 included in primary outcome
analysis
148 randomly assigned to
standard care
1 withdrew
147 included in primary outcome
analysis
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because no primary outcome events had occurred at that 
stage. This implied that the original primary outcome, 
specified early in the pandemic when data on hospital 
admission rates in this population were unknown, 
proved incorrect for this population. The change was 
adopted in line with advice from the data safety 
monitoring com mittee and in accordance with the 
recommendations of the WHO Blueprint for COVID-19 
Therapeutic Trials22 that the primary endpoint should be 
responsive to the eligible patient population and the 
definition of the endpoint should be fine-tuned for the 
pivotal phase, based on the pilot phase of the trial. This 
change was approved by the research ethics committee 
and the Medicines and Healthcare products Regulatory 
Agency on Feb 4, 2021, and implemented before final 
analyses were done. Two other protocol amendments 
were made while the trial was ongoing to broaden 
inclusion criteria to include and ensure the safety 
of participants taking selective serotonin reuptake 






Yes 25 (17%) 27 (18%)
No 122 (83%) 121 (82%)
Diabetes
Yes 11 (7%) 14 (9%)
No 136 (93%) 134 (91%)
Gender
Men 76 (52%) 76 (51%)
Women 71 (48%) 72 (49%)
Age, years 45·5 (14·2) 46·3 (15·5)
COS* 6·36 (3·64) 7·00 (3·87)
COS Plus* 7·66 (4·65) 8·86 (5·25)
Duration of symptoms, days 5·77 (3·49) 6·27 (3·55)
Ethnicity
White 103 (70%) 98 (66%)
Asian or Asian British 23 (16%) 24 (16%)
Black or Black British 6 (4%) 5 (3%)
Mixed 0 4 (3%)
Other† 15 (10%) 17 (11%)
Smoking
Never smoked 81 (55%) 76 (51%)
Former smoker 25 (17%) 26 (18%)
Current smoker 16 (11%) 17 (11%)
Former smoker and current vaper 3 (2%) 4 (3%)
Never smoked and current vaper 0 1 (1%)
Not recorded 16 (11%) 19 (13%)
Residence
Non-residential care 132 (90%) 137 (93%)
Residential care 7 (5%) 3 (2%)
No fixed address 5 (3%) 4 (3%)
Live alone
Yes 17 (12%) 13 (9%)
No 108 (73%) 110 (74%)
Work status
Retired 15 (10%) 23 (16%)
Working 101 (69%) 95 (64%)
Not working 22 (15%) 21 (14%)
Occupation
Not health-care related 77 (52%) 69 (47%)
Health-care worker 20 (14%) 23 (16%)
Laboratory worker 1 (1%) 1 (1%)
Comorbidities
None 107 (73%) 107 (72%)
At least one 33 (22%) 37 (25%)





(Continued from previous column)
Asthma
Yes 26 (18%) 27 (18%)
No 121 (82%) 121 (82%)
History of previous myocardial infarction
Yes 5 (3%) 7 (5%)
No 142 (97%) 141 (95%)
Currently undergoing any cancer treatment
Yes 1 (1%) 0
No 146 (99%) 148 (100%)
Chronic pulmonary disease
Yes 7 (5%) 5 (3%)
No 140 (95%) 143 (97%)
Severity scale score‡
Ambulatory, no limitation of 
activities
61 (41%) 66 (45%)
Limitation of simple activities 85 (58%) 81 (55%)
Admitted to hospital, mild 
disease, no oxygen therapy
1 (1%) 1 (1%)
Pneumonia§
Yes 28 (19%) 34 (23%)
No 119 (81%) 114 (77%)
Swab results¶
Positive 76 (52%) 76 (51%)
Negative 41 (28%) 38 (26%)
Failed assay 0 3 (2%)
Not available 30 (20%) 31 (21%)
Data are n (%) or mean (SD). COS=core outcome set. *COVID-19 COS score of 
clinical symptoms is a total score of six common and important clinical 
symptoms, each scored as 0 (no), 1 (mild), 2 (moderate), or 3 (significant); 
an amended version, COS PLUS, contains an additional two clinical symptoms, 
anosmia and dysgeusia; COS scores range 0–18 and COS Plus scores 0–24, 
with higher scores indicating more severe symptoms. †Other includes Chinese, 
any other ethnic group, and not stated. ‡Severity scale scores range 0–8, 
with higher scores indicating the most severe status, death. §Pneumonia is 
defined as consolidation on a chest x-ray, if a chest x-ray was not taken it is 
assumed there was no pneumonia. ¶Swab test results are only available for those 
who had a COVID-19 swab at randomisation.
Table 1: Baseline characteristics and concomitant treatments of the 
intention-to-treat population
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Based on WHO recommendations that a pilot phase 
with 100 patients would be sufficient to inform follow-
on clinical research,22 an interim analysis was planned 
to establish a definitive sample size. Following the 
revision to the primary outcome and based on masked 
data from the pilot phase, the definitive sample size 
was determined. Assuming a 15% rate of all-cause 
hospital admission or death in the standard care group, 
we estimated that a minimum of 276 participants 
providing primary endpoint data would provide 
80% power and 5% (two-sided) significance to detect a 
difference from 15% to 5% in the azithromycin group, 
a relative reduction of 66%. To allow for 5% loss to 
follow-up we therefore aimed to recruit a minimum of 
291 participants. The full statistical analysis plan is in 
the appendix (pp 40–86).
For the primary outcome, the difference in proportions 
between the treatment groups was assessed using a 
χ² test and a 5% (two-sided) significance level. Adjusted 
analysis was done using logistic regression with 
progression as the binary outcome, adjusting for the 
following stratification factors: centre, hypertension, 
diabetes, and sex. A supporting analysis was also done to 
further adjust for the following important prognostic 
variables: age 65 years and older, presence of chronic 
lung disease, and treatment for cancer. Time-to-event 
analysis was also done to explore whether the active 
treatment delays progression. The success of the trial 
was based on the adjusted analysis. Both relative and 
absolute differences in proportions are reported together 
with 95% CIs. Other binary outcomes were assessed 
using similar methods. Peak severity of illness was 
considered a categorical variable and assessed using 
ordinal logistic regression analysis. The change in 
severity scale score from baseline was summarised on a 
continuous scale using means, SDs, medians, IQRs, and 
ranges. We explored consistency of results for the 
following prespecified stratification factors: hypertension, 
diabetes, sex, and age using treatment by variable 
interaction tests and forest plots. Analyses were done 





Comparison of proportions Time-to-event, hazard 
ratio (95% CI), p value
Odds ratio (95% CI), p value Risk difference 
(95% CI)
Primary outcome
Hospitalisation or death (ITT) 15/145 (10%) 17/147 (12%) ·· ·· ··
Unadjusted ·· ·· 0·88 (0·42 to 1·84), 0·74 –1·2% (–8·4 to 5·9) 0·79
Adjusted ·· ·· 0·91 (0·43 to 1·92), 0·80 –1·0% (–8·0 to 6·1) 0·95 (0·46 to 1·96), 0·89
Fully adjusted ·· ·· 0·91 (0·42 to 1·97), 0·82 –1·2% (–8·2 to 5·7) 0·99 (0·49 to 2·00), 0·99
Hospitalisation or death 
(ITT positive)
11/75 (15%) 11/75 (15%) ·· ·· ··
Unadjusted ·· ·· 1·00 (0·40 to 2·47), 1·00 0·0% (–11·3 to 11·3) 0·78
Adjusted ·· ·· 1·02 (0·40 to 2·57), 0·97 0·3% (–10·8 to 11·4) 1·17 (0·49 to 2·77), 0·72
Full adjusted ·· ·· 1·11 (0·43 to 2·90), 0·83 0·8% (–10·1 to 11·7) 1·30 (0·52 to 3·21), 0·57
Secondary outcomes
Level 2 or 3 ventilation or death 2/145 (1%) 2/147 (1%) p=1·00 ·· ··
All-cause mortality 1/145 (1%) 1/147 (1%) p=1·00 ·· ··
Progression to pneumonia 0/119 2/114 (2%) p=0·24 ·· ··
Comparisons for the primary outcome were performed using a logistic regression model adjusted for stratification factors centre, hypertension, diabetes, and sex (adjusted), 
or fully adjusted for centre, hypertension, diabetes, sex, age 65 years and older, presence of chronic lung disease, and treatment for cancer. Comparisons for the secondary 
outcomes were performed using Fisher’s exact test because of small numbers of events. ITT=intention to treat.
Table 2: Comparison of primary and secondary binary outcomes, and time-to-event in the ITT populations
Figure 2: Time to hospital admission, length of stay, and time to death in the 32 participants admitted to 
hospital during the study
One participant in the azithromycin group was known to have been admitted to hospital but exact dates were not 
available so details of their stay could not be included in the plot.








Time from randomisation (days)
First admission Second admission Death
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Primary and safety analyses were based on the intention-
to-treat (ITT) population, defined as all randomly assigned 
patients analysed according to their randomised allocation. 
A supplementary ITT population (ITT positive) was 
defined as all randomly assigned patients with a positive 
baseline COVID-19 test based on baseline swabs. This trial 
was registered with ClinicalTrials.gov (NCT04381962) and 
EudraCT (2020-001740-26).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
From June 3, 2020, to Jan 29, 2021, 1192 patients were 
screened, of whom 298 were enrolled in the trial 
(figure 1; appendix p 10). Three participants withdrew 
consent and requested removal of all data collected 
so are not presented in baseline data. Of the 
295 participants, 147 were randomly assigned to 
azithromycin plus stan dard care and 148 were randomly 
assigned to standard care alone. Three of 295 patients 
withdrew consent after randomisation (appendix p 23); 
thus, data on the primary outcome were available from 
292 participants. Deviations from protocol are shown in 
the appendix (p 24).
Characteristics of participants assigned to azithromycin 
and to standard care were similar (table 1; appendix 
pp 12–22). The mean participant age was 45·9 years 
(SD 14·9); 152 (52%) of 295 were men and 143 (49%) were 
women; 201 (68%) were White, 47 (16%) were Asian or 
Asian British, 11 (4%) were Black or Black British, and 
36 (12%) were Mixed or other race; 70 (24%) participants 
had comorbidities; and the median duration of symptoms 
before enrolment was 6·02 days (3·52). 246 (83%) par-
ticipants had cough and 225 (76%) had dyspnoea at 
presentation (appendix p 18). Enrolment was based on a 
clinical diagnosis of highly probable COVID-19, but the 
definitive results of naso pharyngeal swabs for SARS-CoV-2 
PCR were available from 231 individuals, of which 
152 (66%) were positive, and constituted the ITT positive 
population (76 azithro mycin and 76 standard care). 
143 (97%) of 147 participants allocated to azithromycin 
commenced treatment, with 76 (52%) achieving full 
compliance (taking a median 28 tablets [IQR 28–28]), 
51 (35%) non-compliant, taking a median 6 tablets 
(IQR 2–17), and compliance was unknown in 20 (14%; 
appendix p 23).
15 (10%) of 145 participants randomly assigned to 
azithromycin and 17 (12%) of 147 participants randomly 
assigned to standard care were admitted to hospital or 
died. The primary endpoint, using the prespecified 
adjusted analysis, was not significantly different between 
the azithromycin and control groups (adjusted OR 0·91 
[95% CI 0·43–1·92], p=0·80; table 2; appendix pp 24–25). 
There was no difference in the time to hospitalisation 
(adjusted hazard ratio [HR] 0·95 [95% CI 0·46–1·96], 
p=0·89; table 2, figures 2, 3A; appendix p 26). In the ITT 
positive population there were also no differences in the 
combined primary outcome of hospitalisation or death 
(adjusted OR 1·02 [0·40–2·57], p=0·97) or time to 
hospitalisation (HR 1·17 [0·49–2·77]), p=0·72; figure 3B, 
table 2). Additionally, unadjusted and fully adjusted 
analyses (further adjusted for age, chronic pulmonary 
disease, and presence of cancer) were done, as well as 
analyses in the per-protocol population. None of these 
analyses demonstrated significant differences between 
the treatment groups (appendix pp 37–38). We did not 
observe heterogeneity of effect across subgroups with 
risk factors for severe disease (older age, male sex, 
hypertension, and diabetes; appendix p 38).
Two participants (1%) in each group required level 2 or 3 
ventilation or died. Because of the very low number of 
events, Fisher’s exact test was used to compare the 
azithromycin and control groups, and results showed no 
significant differences (table 2). The level of oxygen 
support required by each participant during hospital 
admission is summarised in the appendix (p 27). The 
number of deaths from all-causes and participants 
progressing to pneumonia were similarly very low with no 
differences between the two groups (table 2). No 
Figure 3: Kaplan-Meier plot of time to hospital admission in the intention-to-treat population (A) and in the 
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participants progressed to severe pneumonia during the 
trial. Full details of pneumonia status at baseline and 
follow-up are in the appendix (p 28). Analyses of these 
outcomes were also repeated on the ITT positive 
population, with no significant differences (appendix p 26).
Most participants had severity scores of 0 or 1 at baseline 
and at days 14 and 28 (figure 4; appendix pp 29–30). The 
peak severity score during follow-up was calculated for 
each participant with data available. 62 (50%) of 
124 participants randomly assigned to azithromycin and 
60 (46%) of 130 participants randomly assigned to stan dard 
care reported no limitation of activities as their highest 
follow-up severity score (table 3; appendix pp 31–33). 
49 (40%) in the azithromycin group and 57 (44%) in the 
standard care group reported limitation of simple activities 
as their peak score. There was no significant difference 
between the two groups in terms of peak severity score 
(adjusted OR 0·91 [95% CI 0·57–1·46], p=0·69). The 
analysis was repeated for the ITT positive population, with 
no significant differences observed (appendix p 32). In an 
exploratory analysis, the COVID-19 Core Outcome Set 
Plus scores were similar in the two groups at 14 days 
(mean score 7·62 [SD 5·11] in the azithromycin group vs 
7·47 [5·19] in the standard care group; ITT population) and 
28 days (3·06 [3·61] vs 3·38 [3·52]; ITT population) after 
randomisation (appendix pp 34–36).
During follow-up, additional antibiotics were co- 
prescribed in 23 (16%) of 147 participants in the 
azithromycin group and 38 (26%) of 148 in the standard 
care group (appendix p 39). Use of inhaled or systemic 
corticosteroids was not recommended in contemporary 
UK guidelines for those not admitted to hospital, 
although inhaled corticosteroids were co-prescribed in 
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Standard care, day 0
10 2 3 4 5 6 7 8
Severity scale score
Standard care, day 14
10 2 3 4 5 6 7 8
Severity scale score
Standard care, day 28
Azithromycin group 
(n=124)
Standard care group 
group (n=130)
Ambulatory, no limitation of activities 62 (50%) 60 (46%)
Limitation of simple activities 49 (40%) 57 (44%)
Admitted to hospital, mild disease, no oxygen therapy 3 (2%) 2 (2%)
Admitted to hospital, oxygen by conventional delivery 
system ≤40% mask or nasal prongs
5 (4%) 10 (8%)
Admitted to hospital, oxygen by conventional delivery 
system >40% mask
3 (2%) 0
Admitted to hospital, receiving non-invasive 
mechanical ventilation or receiving high-flow oxygen 
therapy (>15 L/min), or continuous positive airway 
pressure
1 (1%) 1 (1%)
Death 1 (1%) 1 (1%)
Data are n (%). The adjusted* odds ratio for peak severity scores was 0·91 (95% CI 0·57–1·46), p=0·69. *Adjusted for 
the stratification factors centre, hypertension, diabetes, and sex.
Table 3: Comparison of peak severity scores in the intention-to-treat-population
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nine (6%) participants receiving azithromycin and 
19 (13%) receiving standard care, while systemic 
corticosteroids were co-prescribed in 16 (11%) receiving 
azithromycin and 16 (11%) receiving standard care 
(appendix p 39). No serious adverse events were recorded 
in either treatment group during follow-up. Three (2%) 
of 145 participants randomly assigned to azithromycin 
and four (3%) of 147 participants randomly assigned to 
standard care reported a com plication during hospital 
stay (appendix p 37).
Discussion
In this trial of people with clinically diagnosed mild-to-
moderate COVID-19 managed without hospital admis-
sion, adding azithromycin to standard care treatment did 
not reduce the risk of subsequent hospital admission or 
death, or of time to hospital admission.
Three recent, large, open-label, randomised con-
trolled trials have assessed the use of azithromycin in 
patients admitted to hospital with severe COVID-19, 
and none have found a clinically significant benefit in 
those populations. COALITION I randomly assigned 
667 patients admitted to hospital with COVID-19 to 
standard care, hydroxychloroquine, or hydroxychloroquine 
with azithromycin 500 mg for 7 days and found no 
difference in clinical status on an ordinal score at 15 days 
between hydroxychloroquine with azithromycin and 
hydroxychloroquine (OR 0·82 [95% CI 0·47–1·43]; 
p=1·00).16 Likewise, COALITION II randomly assigned 
447 patients admitted to hospital to azithromycin 500 mg 
daily for 10 days or standard care, and again found no 
difference in day 15 ordinal score (OR 1·36 [0·94–1·97], 
p=0·11).13 RECOVERY randomly assigned 7763 of its 
participants to azithromycin 500 mg for 10 days or 
standard care and found no difference in 28-day mortality 
(rate ratio 0·97 [95% CI 0·87–1·07], p=0·50), length 
of stay, or invasive mechanical ventilation and death.15 
However, none of these trials assessed the potential for 
efficacy in early, milder disease.
Three trials in primary care have randomly assigned 
participants with early disease to 3 days23 or 5 days24,25 of 
therapy. Azithromycin was assessed as standalone 
therapy only in the PRINCIPLE trial;23 a large, adaptive 
platform trial in the UK, which randomly assigned 
540 participants to 3 days treatment with azithromycin 
500 mg daily versus 875 participants to standard care. 
This study found no difference in time to first reported 
recovery (HR 1·08 [95% Bayesian credibility interval 
[BCI] 0·95 to 1·23]), and, although only 3% of participants 
were admitted to hospital, there was no significant 
difference between groups (absolute benefit in 0·3% 
[95% BCI –1·7 to 2·2]). The remaining two trials also 
used short courses of azithromycin 500 mg for 1 day 
followed by 250 mg for 4 days and taken in conjunction 
with hydroxychloroquine. Q-PROTECT recruited healthy, 
SARS-CoV-2-positive men in a quarantine site in Qatar 
and found no difference in time to virological cure 
(p=0·82),24 with low rates of hospital admission in all 
groups (2·4%). A study in the USA assessed progression 
to lower respiratory tract infection, hospital admission, 
or death and time to viral clearance in SARS-CoV-2-
positive outpatients, but was stopped early for futility 
because of a low rate of clinical outcomes in this 
population, and found no difference in the co-primary 
outcome of time to virological clearance (HR 1·25 
[95% CI 0·75 to 2·07], p=0·39).25 No studies have 
assessed azithromycin in patients presenting to hospital 
with substantial symptoms, but early enough in the 
disease process to be managed in ambulant care, and 
neither have previous studies assessed high-dose, long-
duration azithromycin therapy in early disease.
Our study investigated this intermediate population 
with early disease, but at high risk of deterioration, in 
whom 11% required subsequent hospital admission. 
Therefore, our population represents those with the 
optimal chance of demonstrating clinical benefit in early 
disease. We did not observe a significant difference in 
our primary outcome. Given the small absolute event 
rates for the primary outcome in our study, a smaller but 
clinically relevant effect cannot be entirely ruled out, but 
would be unlikely to change clinical practice. Nonetheless, 
this finding, taken together with clear negative results 
across the disease course from early, low-risk patients, 
to patients admitted to hospital with severe disease, 
provides strong confirmation that azithromycin is not 
effective in treating COVID-19.
A unique feature of ATOMIC2 was its successful 
implementation at the interface between community and 
secondary care, which is often a challenging location to 
recruit due to pressures for rapid clinical decision 
making. This implementation was made possible by 
electronic screening, consent, and recruitment. This 
platform, along with simplicity and broad inclusion 
criteria, have facilitated a second strength of the study: 
inclusion of an ethnically diverse population, with 
32% of participants recruited from Black and minority 
ethnic (BAME) backgrounds. This is important as 
COVID-19 is a global pandemic, with a disproportionate 
impact on BAME groups, yet these groups are under-
represented in many COVID-19 trials, which might 
reduce external validity.26 Another strength of our study is 
that in contrast to other studies, the high dose (500 mg 
daily) and long duration (14 days) of azithromycin was 
used to ensure that we adequately assessed potential 
antiviral, antibacterial, and anti-inflammatory benefits. 
COVID-19 is considered to have a distinct early viraemic 
phase and a late inflammatory phase in some individuals, 
and therefore assessment of antiviral activity needs to be 
early in the disease course before onset of severe disease.20 
Conversely it was not known what doses might be 
required to produce an adequate anti-inflammatory effect 
so it was necessary to give a high dose of long duration to 
ensure the anti-inflammatory effect was tested throughout 
the late stage of innate or acute phase inflammatory 
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cytokine dysregulation.1 An additional strength is that we 
were also able to exclude a significant benefit from 
azithromycin’s antibiotic effects, which was not possible 
in studies of patients in hospital where co-prescribing of 
β-lactam and other antibiotics was common.15 Our data 
show that secondary bacterial infection is not a major 
driver of hospital admission in this population.
A limitation of our trial is that it was open-label, because 
of the difficulty obtaining appropriate placebos early in 
the pandemic and is therefore at risk of bias particularly 
on patient-reported outcomes. However, our choice of 
hospital admission and death as the primary outcome is 
unlikely to be markedly influenced by selection, detection 
or observer bias. Detection of admission to hospital has 
been easier because of restricted movement during 
lockdowns, from use of regional and national electronic 
health records, and by systematic contacting of all 
participants, with more than 95% follow-up. Moreover, a 
placebo effect from perceived benefits of treatment would 
tend towards a positive effect of azithromycin, which was 
not observed. Knowledge of treatment allocation might 
also lead to a tendency to more antibiotic prescribing in 
the placebo group—an effect we observed—which would 
tend to prejudice against azithromycin as an antibiotic, 
although concomitant use of macrolides specifically was 
prohibited by the protocol. A second limitation is that, 
like other studies,23 we used a clinical diagnosis for 
inclusion, rather than requiring PCR confirmation, and 
PCR data were not available for all participants—
particularly at the early stages of the pandemic in the UK 
where low testing capacity was directed to patients who 
needed admission to hospital. While it is likely some 
participants who did not ultimately have COVID-19 might 
have been enrolled, this decision reflects the situation in 
many urgent care settings globally where PCR confir-
mation is not immediately available, and enhances the 
generalisability of our findings. Nonetheless, SARS-CoV-2 
was detected in 66% of those with successful PCR assays 
in our study, which is much higher than the 31% PCR-
positive rate observed in PRINCIPLE,23 and study results 
were similar in the overall ITT group and the predefined 
PCR-positive subgroup analysis. An ITT analysis was 
selected as the most appropriate approach to establish 
whether this intervention affects clinical outcomes. While 
throat swab PCR assays have high specificity, they have 
low sensitivity in routine clinical practice, and conse-
quently where there is a high pre-test probability for 
COVID-19, as was the situation in those enrolled, a 
negative PCR result has a low negative predictive value 
and most negative results will be false negatives.27 A third 
limitation is the relatively young mean age of the study 
population (45·9 years), which reduces the proportion 
who are likely to have severe disease. Nonetheless, 
the primary outcome occurred in more than 10% of 
participants, and globally, individuals of similar age could 
have been receiving azithromycin therapy in many 
countries. Other limitations are incomplete compliance 
to the long treatment regimen in some individuals and 
absence of data on microbiology or long-term outcomes 
beyond 28 days.
In the past year, more than 40 clinical trials of 
azithromycin in COVID-19 have been registered.1 Given 
positive data from in silico and in vitro2 screens and data 
showing suppression of innate inflammatory cytokines 
in vitro, and clinical trial data in non-SARS-CoV-2 
alphacoronaviruses and betacoronaviruses,7 why might 
these have not translated into clinical efficacy? Other 
antiviral molecules have had little clinical effect in 
COVID-19 compared with immunosuppressive thera pies, 
except in very early disease. In common with influenza, 
antivirals are probably only efficacious in the early 
viraemic disease stage and are ineffective in severe 
disease, which is more closely linked to differences in host 
immune factors. In contrast to influenza A pandemics, 
the antibacterial effects of azithromycin are unlikely to 
translate into significant clinical benefit in a disease where 
secondary bacterial pneumonia is rare.28 While many 
studies have shown azithromycin sup pression of innate 
cytokines known to be key mediators of severe disease, 
including IL-1β, IL-6, CXCL-8, TNF, and GM-CSF, some 
of these data might be confounded by antibacterial effects 
in the original studies, and it might be that the suppression 
achieved by azithromycin is simply insufficient to 
overcome the overwhelming cytokine production 
triggered by this virus in susceptible individuals.
We found no evidence of safety concerns associated 
with azithromycin, despite the quite high dose and 
long course prescribed. In particular, there were no 
adverse cardiac events; a concern raised by studies of 
azithromycin and hydroxychloroquine co-prescribing.29 In 
a Danish cohort analysis of 10·6 million prescrip tions, 
azithromycin prescribing has been associated cardio-
vascular death (rate ratio 2·85 [95% CI 1·13–7·24]) 
compared with no antibiotics, but this is probably because 
of the underlying indication because, when compared 
with penicillin V, there was no increased risk once 
adjusted for propensity scores (rate ratio 0·93 [0·56–1·55]).30 
This analysis was performed in a population with a low 
baseline risk of cardiovascular death, and it should be 
noted that we excluded patients with a prolonged 
QT interval at baseline electrocardiogram. Nonetheless, 
there are considerable population risks of unwarranted 
prescribing of azithromycin, which is a highly valuable 
antimicrobial and yet has a particularly high propensity 
for inducing antimicrobial resistance, both to macrolides 
and to other drug classes, including β-lactam antibiotics.31
In conclusion, our findings in mild-to-moderate 
COVID-19 managed in ambulatory care, taken together 
with trials in early disease in primary care and from trials 
in patients admitted to hospital with severe disease, 
suggest that azithromycin does not reduce hospital 
admissions, respiratory failure, or death compared with 
standard care, and should not be used in the treatment of 
COVID-19.
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